Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Drug Cards Daily

#38: esomeprazole (Nexium) | Get Stomach Acid and H. pylori Infection Under Control

05 Jul 2021

Description

Esomeprazole is available over the counter and by prescription. The commonly known brand name is Nexium. Esomeprazole is a substituted benzimidazole proton pump inhibitor (PPI). It comes in a delayed release capsule and as delayed release granule packets. When treating GERD and other hypersecretory conditions a typical dosing range is between 20-40 mg po qd-bid. Esomeprazole is also used as part of a multi-drug regimen for treating  H. pylori infection. The mechanism of action behind esomeprazole is through the suppression of acid secretion by inhibiting hydrogen-potassium ATPase. Esomeprazole is the S-enantiomer of omeprazole (Prilosec). Since esomeprazole affects stomach acid it may alter how well other drugs work. For example, absorption of drugs may decrease which may lead to a decrease in efficacy of those drugs. Esomeprazole is best when taken 1 hour before a meal and best if taken before the first meal of the day. If needed, the capsule can be opened.  Go to DrugCardsDaily.com for my episode show notes which will contain a drug summary, quiz, and a link to FREE drug card sheets. SUBSCRIBE on Spotify or Apple Podcasts or search for us on your favorite place to listen to podcasts. I will go over the Top 100-200 Drugs as well as throwing in some recently released drugs that peak my interest. Also, if you’d like to say hello, suggest a drug, or leave any constructive feedback on the show I’d really appreciate it! Leave a voice message at anchor.fm/drugcardsdaily or message us through twitter @drugcardsdaily

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.